X0306 4 2018-01-30 0 0001693664 ARMO BioSciences, Inc. ARMO 0001487815 Cui Xiangmin C/O DECHENG CAPITAL 35 SI NAN ROAD, 3RD FLOOR SOUTH SHANGHAI F4 200020 CHINA 1 0 0 0 Common Stock 2018-01-30 4 C 0 1214700 A 1214700 I By Decheng Capital China Life Sciences USD Fund II, L.P. Series C-1 Convertible Preferred Stock 2018-01-30 4 C 0 1214700 0.00 D Common Stock 1214700 0 I By Decheng Capital China Life Sciences USD Fund II, L.P. The total represents shares received upon conversion of shares of Series C-1 Convertible Preferred Stock. Each share of Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. These Shares are held of record held by Decheng Capital China Life Sciences USD Fund II, L.P. (Decheng Capital). Decheng Capital Management II (Cayman), LLC (Decheng Management) serves as the general partner of Decheng Capital and possesses the power to direct the voting and disposition of the shares owned by Decheng Capital. The Reporting Person is the sole director and sole voting shareholder of Decheng Management and has sole voting and dispositive power over the shares held by Decheng Capital. The Reporting Person disclaims beneficial ownership of the shares held by Decheng Capital, except to the extent of his pecuniary interest. Each of Decheng Capital and the Reporting Person disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. /s/ Scott Paraker, Attorney-in-Fact 2018-01-30